Lori R. Roth

Lori R. Roth

Auto-generated profile, based on publicly available information

Lori R. Roth

Departments of Internal Medicine (L.C., L.R.R., J.L.G.), University of Texas Southwestern Medical Center, Dallas, TX

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
JGJustin L. Grodin
Justin L. Grodin
AGAnand Gupta
Anand Gupta
IRIshan Rison
Ishan Rison
JKJulia Kozlitina
Julia Kozlitina
LSLorena Saelices
Lorena Saelices
JLJames A. de Lemos
James A. de Lemos
BACKGROUND: To better define the importance of the amyloidogenic p.V142I TTR allele across the life span of a carrier, we leveraged data from All of Us to provide a generalizable assessment of the population-level burden of cardiovascular risk and estimate the age at disease onset. METHODS: We included self-identifying Black participants in All of Us who provided genomic data (N=77 767). The exposure of interest was p.V142I TTR carrier status (N=2213). Outcomes included incident heart failure (HF), atrial fibrillation, and carpal tunnel syndrome. RESULTS: The median (interquartile range) age at enrollment was 56 (42–64) years. For the subset with genetic ancestry data (N=50 516), the p.V142I TTR carrier frequency was 3.5% (N=1771) among those with African ancestry. After adjustment for age and traditional risk factors, p.V142I TTR carrier status was associated with a greater risk of HF (odds ratio, 1.56 [95% CI, 1.22–1.99]; P =0.001), atrial fibrillation (odds ratio, 1.3 [95% CI, 1.08–1.90]; P =0.013), and carpal tunnel syndrome (odds ratio, 1.94 [95% CI, 1.43–2.63]; P 0.05 for all), their presence substantially augmented the risk of HF over a lifetime. CONCLUSIONS: p.V142I TTR carriers are at an increased risk of HF and atrial fibrillation, beginning during the sixth decade of life. HF risk rises in a dose-dependent manner with other nonamyloid-related HF risk factors, highlighting the importance of aggressive treatment of HF risk factors among carriers. These observations also confirm the clinical relevance of the p.V142I TTR variant for individuals of African ancestry and underscore the importance of efforts to increase diagnoses, implement TTR-targeted therapies, and evaluate screening strategies for variant transthyretin cardiac amyloidosis.

1 April 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JSJoshua Saef
Joshua Saef
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
LILauren Ives
Lauren Ives
LRLori R. Roth
Lori R. Roth
JGJustin L. Grodin
Justin L. Grodin
WTW.H. Wilson Tang
W.H. Wilson Tang
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural history. Patients’ TTR genotype may guide family screening as more treatments and preventive strategies become available. An efficient, intuitive means of determining pretest genetic risk may better inform patients/clinicians when pursuing genetic testing. Methods: This is a cohort study of 767 consecutive patients diagnosed with ATTR-CM who underwent genetic testing. Classification and regression trees (CART) analysis created a decision tree assessing likelihood of carrying a pathologic TTR gene variant. Age, sex, and race were used as independent variables. Logistic regression was also performed to model probability of pathologic TTR genotype. The primary outcome was the decision tree’s accuracy in 2 separate institutions’ ATTR-CM registry. Results: In our study cohort, 208 patients (27.1%) had ATTRv. Race has served most efficiently as the root node followed by age and sex in a CART algorithm, and showed 88.2% accuracy (75.3% sensitivity, 93.9% specificity) in the validation cohort. The odds of having a TTR gene variant were greater in Black patients compared with non-Black patients (OR, 34.6 [95% CI, 20.5–58.3]; P <0.001). Non-Black patients with ATTR-CM aged 69 years and older had <4% risk of having a predisposing mutation. Conclusions: This CART algorithm incorporating age, sex, and race was able to determine which patients with ATTR-CM have pathogenic TTR mutations with high specificity. Non-Black patients diagnosed at age 69 years or older with ATTR-CM have a low likelihood to have ATTRv.

5 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PBParker T. Bassett
Parker T. Bassett
BNBinh A. Nguyen
Binh A. Nguyen
VSVirender Singh
Virender Singh
PGPatrick T. Garrett
Patrick T. Garrett
JMJames Moresco
James Moresco
LSLorena Saelices
Lorena Saelices
Immunoglobulin light chain (AL) amyloidosis is a systemic disorder caused by the misfolding and aggregation of free immunoglobulin light chains (LCs) secreted by abnormal plasma cells. The resulting amyloid fibrils deposit in multiple organs, leading to progressive dysfunction and increased morbidity and mortality. Despite recent advances, the molecular determinants of LC aggregation and phenotypic variability remain poorly understood. Structural characterization of ex-vivo fibrils provides key insights into these pathogenic processes. Here, we report cryo-electron microscopy structures of cardiac AL amyloid fibrils derived from an IGLV6 light chain. The fibrils display two distinct morphologies composed of single and double protofilaments, each adopting a previously unobserved fold. Comparison with previously reported AL fibril structures reveals that while individual mutations can alter the local conformation, IGLV6-derived fibrils share conserved structural motifs that may underlie common aggregation pathways. These findings expand the disease structural landscape and highlight sequence-dependent yet structurally constrained mechanisms of LC fibril formation.

18 November 2025 in Circulation
Verified
Journal Article
Closed access
LCLeonard Chiu
Leonard Chiu
AAAimaz Afrough
Aimaz Afrough
UNUrooba Nadeem
Urooba Nadeem
DJDeborah Jebakumar
Deborah Jebakumar
LRLori R. Roth
Lori R. Roth
JGJustin L. Grodin
Justin L. Grodin